Contents

Highlights of This Issue 753

SPECIAL FEATURES

CCR Translations

755
Predictive Biomarkers to Anti-VEGF Therapy: Progress toward an Elusive Goal
Rekha Gyanchandani and Seungwon Kim
See article, p. 929

Molecular Pathways

758
Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed By Oncolytic Vesiculoviruses
Douglas J. Mahoney and David F. Stojdl

Review

764
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki and Paul Kleihues

HUMAN CANCER BIOLOGY

773
Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Mark L. McCleland, Adam S. Adler, Laura Deming, Ely Cosino, Leslie Lee, Elizabeth M. Blackwood, Margaret Solon, Janet Tao, Li Li, David Shames, Erica Jackson, William F. Forrest, and Ron Firestein

785
Reciprocal Interactions between Tumor-Associated Macrophages and Osteopontin/CD44 Promote Tumorigenesis in Colorectal Cancer
Guanhua Rao, Hongyi Wang, Baowei Li, Li Huang, Danfeng Xue, Xiaohui Wang, Haijing Jin, Jun Wang, Yushan Zhu, Youyong Lu, Lei Du, and Quan Chen

798
SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
Michael S. Leibowitz, Raghvendra M. Srivastava, Pedro A. Andrade Filho, Ann Marie Egloff, Lin Wang, Raja R. Seethala, Soldano Ferrone, and Robert L. Ferris

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

INFLUENCE OF HUMAN OATP1B1, OATP1B3, AND OATP1A2 ON THE PHARMACOKINETICS OF METHOTREXATE AND PACLITAXEL IN HUMANIZED TRANSGENIC MICE
Evita van de Steeg, Anita van Esch, Els Wagenaar, Kathryn E. Kenworthy, and Alfred H. Schinkel

BLOCKED AUTOPHAGY USING LYSOSOMOTROPIC AGENTS SENSITIZES RESISTANT PROSTATE TUMOR CELLS TO THE NOVEL AKT INHIBITOR AZD5363
Francois Lamoureux, Christian Thomas, Claire Crafter, Masafumi Kumanou, Fan Zhang, Barry R. Davies, Martin E. Gleave, and Amina Zoubeidi

CANCER THERAPY: PRECLINICAL

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

821

833

845

855

855

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

The Journal of Clinical and Translational Research www.aacrjournals.org
Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Nilesh A. Patankar, Julia Pritchard, Mariska van Grinsven, Maryam Osooly, and Marcel B. Bally

IMAGING, DIAGNOSIS, PROGNOSIS

DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett’s Esophagus
Muhammad A. Alvi, Xinxue Liu, Maria O’Donovan, Richard Newton, Lorenz Wernisch, Nicholas B. Shannon, Kareem Shariff, Massimiliano di Pietro, Jacques J.G.H.M. Bergman, Krish Ragunath, and Rebecca C. Fitzgerald

The Immune Signature of CD8$^+$ CCR7$^+$ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Malgorzata Czystowska, William Gooding, Miroslaw J. Szczepanski, Andres Lopez-Abaitero, Robert L. Ferris, Jonas T. Johnson, and Theresa L. Whiteside

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde, Adrian M. Jubb, Dafeng Chen, Nicole F. Li, Yu Gloria Meng, Coen Bernaards, Rebecca Elliott, Stefan J. Scherer, and Daniel S. Chen

See commentary, p. 755

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarrokri, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engkelke, Mikkael A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radivojevitch, and Yogen Saunthararajah

CANCER THERAPY: CLINICAL

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon, Morris D. Groves, Patrick Y. Wen, Louis Nabors, Tom Mikkelson, Steve Rosenfeld, Jeffrey Raizer, Jorge Barriuso, Roger E. McLendon, A. Benjamin Suttle, Bo Ma, C. Martin Curtis, Mohammed M. Dar, and Johann de Bono

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

LETTERS TO THE EDITOR

Long-term Prospective Population PK Study in GIST Patients—Letter
Etienne Chatelut, Peggy Gandia, Verena Gotta, and Nicolas Widmer

Long-term Prospective Population PK Study in GIST Patients—Response
Ron H.J. Mathijssen, Peter de Bruijn, Karel Eechoute, and Alex Sparreboom

CORRECTION

Correction: Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarrokri, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engkelke, Mikkael A. Sekeres, Ramon Tiu, Jaroslav Maciejewski, Tomas Radivojevitch, and Yogen Saunthararajah

See commentary, p. 755
ABOUT THE COVER

The image displays a human prostate cell line (PC-3) that has been stained with antibodies against the autophagy marker Light Chain 3 (LC3; green) after rapamycin treatment. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles, as shown by green puncta. Tumor cell nuclei are visualized by DAPI (blue). For details, see the article by Lamoureux and colleagues on page 833 of this issue.